These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
527 related items for PubMed ID: 30893533
1. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. N Engl J Med; 2019 Mar 21; 380(12):1128-1138. PubMed ID: 30893533 [Abstract] [Full Text] [Related]
2. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, McDougle CJ, Wisner KL, Gray KJ, Pennell PB, Lester B, Zhu Y, Mogun H, Huybrechts KF. JAMA Psychiatry; 2024 May 01; 81(5):477-488. PubMed ID: 38265792 [Abstract] [Full Text] [Related]
3. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Winterstein AG, Gerhard T, Shuster J, Saidi A. Pediatrics; 2009 Jul 01; 124(1):e75-80. PubMed ID: 19564272 [Abstract] [Full Text] [Related]
4. [Risk of psychosis with treatment for ADHD]. Kooij JJS. Ned Tijdschr Geneeskd; 2020 Aug 27; 164():. PubMed ID: 32940981 [Abstract] [Full Text] [Related]
5. Risk of Injury According to Attention Deficit Hyperactivity Disorder, Comorbid Mental Illness, and Medication Therapy. Merrill RM, Thygerson SM, Palmer CA. Pharmacopsychiatry; 2016 Mar 27; 49(2):45-50. PubMed ID: 26829453 [Abstract] [Full Text] [Related]
6. [Supervised off-label prescribing of methylphenidate in adult ADHD]. Carton L, Dondaine T, Deheul S, Marquié C, Brigadeau F, Amad A, Devos D, Danel T, Bordet R, Cottencin O, Gautier S, Ménard O. Encephale; 2019 Feb 27; 45(1):74-81. PubMed ID: 30122296 [Abstract] [Full Text] [Related]
7. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Hollis C, Chen Q, Chang Z, Quinn PD, Viktorin A, Lichtenstein P, D'Onofrio B, Landén M, Larsson H. Lancet Psychiatry; 2019 Aug 27; 6(8):651-658. PubMed ID: 31221557 [Abstract] [Full Text] [Related]
8. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity. Fredriksen M, Dahl AA, Martinsen EW, Klungsøyr O, Haavik J, Peleikis DE. Eur Neuropsychopharmacol; 2014 Dec 27; 24(12):1873-84. PubMed ID: 25453480 [Abstract] [Full Text] [Related]
9. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. Olfson M, Marcus SC, Zhang HF, Wan GJ. J Manag Care Pharm; 2007 Sep 27; 13(7):570-7. PubMed ID: 17874863 [Abstract] [Full Text] [Related]
11. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007. Janols LO, Liliemark J, Klintberg K, von Knorring AL. Nord J Psychiatry; 2009 Nov 27; 63(6):508-16. PubMed ID: 19958258 [Abstract] [Full Text] [Related]
12. Psychosis in a cocaine-dependent patient with ADHD during treatment with methylphenidate. Delavenne H, Duarte Garcia F, Lacoste J, Cortese S, Charles-Nicolas A, Ballon N. Gen Hosp Psychiatry; 2013 Nov 27; 35(4):451.e7-9. PubMed ID: 22739113 [Abstract] [Full Text] [Related]
13. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. Shyu YC, Yuan SS, Lee SY, Yang CJ, Yang KC, Lee TL, Wang LJ. Schizophr Res; 2015 Oct 27; 168(1-2):161-7. PubMed ID: 26363968 [Abstract] [Full Text] [Related]
14. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Kraemer M, Uekermann J, Wiltfang J, Kis B. Clin Neuropharmacol; 2010 Jul 27; 33(4):204-6. PubMed ID: 20571380 [Abstract] [Full Text] [Related]
16. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. JAMA; 1998 Apr 08; 279(14):1100-7. PubMed ID: 9546570 [Abstract] [Full Text] [Related]
17. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Hodgkins P, Shaw M, Coghill D, Hechtman L. Eur Child Adolesc Psychiatry; 2012 Sep 08; 21(9):477-92. PubMed ID: 22763750 [Abstract] [Full Text] [Related]
18. Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series study. Man KKC, Lau WCY, Coghill D, Besag FMC, Cross JH, Ip P, Wong ICK. Lancet Child Adolesc Health; 2020 Jun 08; 4(6):435-443. PubMed ID: 32450123 [Abstract] [Full Text] [Related]
20. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study. Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK. Clin Ther; 2007 Jun 18; 29(6):1168-77. PubMed ID: 17692731 [Abstract] [Full Text] [Related] Page: [Next] [New Search]